Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Abroad (travel likely)RecruitingPHASE2

Conditions

T-cell Acute Lymphoblastic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Northwestern, Chicago, Illinois, United States
Contact: Study coordinator (Shira Dinner, MD) · shira.dinner@nm.org · 312-695-2120

Study leads

Shira Dinner, MD
Study Chair
Northwestern University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Leukemia, Lymphocytic, Chronic, B-Cell · B-Lymphocytic Leukemia, Chronic · B-Cell Chronic Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

T-cell Acute Lymphoblastic Leukemia · T-cell Lymphoma · Mixed Phenotype Acute Leukemia

Abroad (travel likely)RecruitingPHASE2

San Diego, United States · Charlotte, United States

Methods of T Cell Depletion Trial (MoTD)

Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Chronic Myelomonocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Cardiff, United Kingdom · Birmingham, United Kingdom

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Hematologic Malignancy · Acute Leukemia · Remission

Abroad (travel likely)RecruitingPHASE2

Minneapolis, United States